Today's Top Gainer
Note:Top Gainer - Nifty 50 More
NCDs have had notable success in recent history. Corporates are viewing this instrument as the best bet to raise funds and demand from retail and institutional investors is high. While there are inherent risks compared to bank FDs, post tax returns are attractive in many cases. Further, reputed issuers are securing these by a charge on company assets. A word of caution: Always check the credit rating and stay away from low rated paper and issuers with generic or vague fund-raising propositions.
Thyrocare’s high B2B exposure helps it procure reagent at ~70% discount, thereby protecting margins. The 24% revenue ...
Buy Reco. Price: 549.25
Syngene is moving up in the CRO value chain by expanding its research capabilities and foraying in API manufacturing in FY20E. ...
Accumulate Reco. Price: 566.65